Glenmark’s Immune-Boosting Cancer Drug Candidate Gains FDA Approval for Clinical Trials
Glenmark Pharmaceuticals, a leading global pharmaceuticals company, has announced that its investigational drug candidate, GRC 54276, has received approval from the US Food and Drug Administration (FDA) to proceed with…